Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Algoma Central Q3 net earnings rise 37% to CAD 54.18 million; Q3 revenue climbs 26% to CAD 287.75 million

Algoma Central Q3 net earnings rise 37% to CAD 54.18 million; Q3 revenue climbs 26% to CAD 287.75 million

BitgetBitget2026/11/06 12:01
  • Algoma Central's third-quarter 2026 net earnings rose 37% year-over-year to CAD 54.18 million; revenue climbed 26% to CAD 287.75 million.
  • Net earnings included a CAD 8.88 million gain from selling two vessels retired from the Ocean Self-Unloaders Pool.
  • The quarterly dividend rises to CAD 0.31 per share, payable December 1, following a CAD 1 special dividend paid October 21.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Algoma Central Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106925385) on November 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss